Paratek Announces FDA Advisory Committee Date for Omadacycline

BOSTON, June 20, 2018 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today announced that a meeting of the Antimicrobial Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has been scheduled for August 8, 2018 to review the Company’s New Drug Applications (NDAs) for once-daily, oral and intravenous omadacycline. Omadacycline is under review for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). 

The FDA accepted Paratek’s NDA for priority r…


Leave a Reply

Your email address will not be published.